PRESENTATION

Q4 2023 — Earnings presentation

Q4 2023PDF · 24 pages1.0 MB
2023 Fourth Quarter Earnings
(unaudited)
Mike Roman
Chairman of the Board and
Chief Executive Officer
Monish Patolawala
President and Chief
Financial Officer
Bruce Jermeland
Senior Vice President,
Investor Relations

-- 1 of 24 --

2
2023 Q4 Earnings | January 23, 2024. All rights reserved.
This presentation contains forward-looking information about 3M’s financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words
such as “plan,” “expect,” “aim,” “believe,” “project,” “target,” “anticipate,” “intend,” “estimate,” “will,” “should,” “could,” “would,” “forecast” and other words and terms of similar meaning in connection with any discussion of
future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, international trade,
geopolitical, capital markets and other external conditions and other factors beyond the Company’s control, including inflation, recession, military conflicts, natural and other disasters or climate change affecting the operations
of the Company or its customers and suppliers; (2) foreign currency exchange rates and fluctuations in those rates; (3) risks related to certain fluorochemicals, including liabilities related to claims, lawsuits, and government
regulatory proceedings concerning various PFAS-related products and chemistries, as well as risks related to the Company’s plans to exit PFAS manufacturing and discontinue use of PFAS across its product portfolio; (4) risks
related to the proposed class-action settlement (“PWS Settlement”) to resolve claims by public water systems in the United States regarding PFAS, including whether court approval of the PWS Settlement will be obtained,
whether the number of plaintiffs that opt out of the PWS Settlement will exceed current expectations or will exceed the level that would permit 3M to terminate the PWS Settlement (and whether 3M will elect to terminate the
PWS Settlement if this occurs), whether the PWS Settlement is appealed, the timing and amount of payments made under the PWS Settlement, and the impact of the PWS Settlement on other PFAS-related matters; (5) legal
proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company’s Annual Report on Form 10-K for the year ended Dec. 31, 2022 and any subsequent
quarterly reports on Form 10-Q (the “Reports”); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product and service offerings; (8) the availability and cost of purchased
components, compounds, raw materials and energy due to shortages, increased demand and wages, supply chain interruptions, or natural or other disasters; (9) unanticipated problems or delays with the phased implementation
of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company’s information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and
other strategic events resulting from portfolio management actions and other evolving business strategies; (11) operational execution, including the extent to which the Company can realize the benefits of planned productivity
improvements, as well as the impact of organizational restructuring activities; (12) financial market risks that may affect the Company’s funding obligations under defined benefit pension and postretirement plans; (13) the
Company’s credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company's Health Care business,
including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated
amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company's ability to retain talent; potential
impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter
ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the
transaction; (16) matters relating to the proposed spin-off of the Company’s Health Care business; and (17) matters relating to Combat Arms Earplugs (“CAE”), including those relating to the August 2023 settlement that is
intended to resolve, to the fullest extent possible, all litigation and alleged claims involving the CAE sold or manufactured by the Company’s subsidiary Aearo Technologies and certain of its affiliates (“Aearo Entities”) and/or
3M (“CAE Settlement”), including, but not limited to, whether the anticipated participation by plaintiffs in the CAE Settlement will be achieved, whether the number of plaintiffs that participate in the CAE Settlement will meet
current expectations or will fall below the level that would permit 3M to terminate the CAE Settlement (and whether 3M will elect to terminate the CAE Settlement if this occurs), whether there will be a significant number of
future claims by plaintiffs that decline to participate in the CAE Settlement, whether the CAE Settlement is appealed or challenged, matters related to the potential issuance of the equity securities that are contemplated to be
part of the CAE Settlement, the filing of additional, or the outcome of any other pending or future, litigation relating to the products that are the subject of the CAE Settlement, or changes in related laws or regulations. Changes
in such assumptions or factors could produce significantly different results. A further description of these factors is located in the Reports under “Cautionary Note Concerning Factors That May Affect Future Results” and “Risk
Factors” in Part I, Items 1 and 1A (Annual Report) and in Part I, Item 2 and Part II, Item 1A (Quarterly Reports). The Company assumes no obligation to update any forward-looking statements discussed herein as a result of new
information or future events or developments.
Note on non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. Refer to 3M’s January 23, 2024, press release for descriptions of non-GAAP financial measures such as adjusted net sales (and adjusted sales change);
adjusted purchases of property, plant and equipment (also referred to as adjusted capital expenditures); adjusted net cash provided by (used in) operating activities; adjusted free cash flow; adjusted free cash flow conversion;
net debt; adjusted EBITDA (and adjusted EBITDA margin); and various measures that adjust for the impacts of special items. These non-GAAP measures are not in accordance with, nor are they a substitute for, GAAP
measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in that press release.
Forward-looking statements

-- 2 of 24 --

3
2023 Q4 Earnings | January 23, 2024. All rights reserved.
2024 outlook approach
▪ At this time, the 2024 guidance approach
− Includes the Health Care business as part of the company for the full year and
− Does not reflect the potential impact of funding the litigation payments, absent the receipt of the cash payments in the spin (each as
discussed below), therefore no corresponding impact on interest expense/income
▪ The pending spin of the Health Care business remains on track for 1H 2024. 3M expects the business to be spun-off with net leverage of 3
to 3.5 times EBITDA and distribute proceeds of the financing to 3M prior to spin
▪ Management continues to support the Public Water Systems (PWS) and Combat Arms Earplug (CAE) settlements and is working with all
parties and the courts to reach finalization and ultimate implementation
− 3M has not selected from the options available to fund amounts due under the PWS and CAE legal settlements absent receipt of cash
payments in the spin, therefore, has not forecasted the impacts of changes in net debt that may be needed to fund amounts under
these settlements
− For illustrative purposes only, estimated based on the current market and company expectations, in the absence of the receipt of cash
payments in the Spin, the potential adjusted EPS impact from complete debt financing of the legal settlements could be up to ($0.20)
− 3M will treat the dilutive EPS impact of 3M’s option to satisfy $1 billion of the CAE settlement payments via shares as an adjustment in
arriving at results, adjusted for special items
▪ When considering 3M financials post spin, it is not appropriate to simply remove the Health Care business
▪ 3M will host an investor meeting following the spin of Health Care
Notes on guidance

-- 3 of 24 --

4
2023 Q4 Earnings | January 23, 2024. All rights reserved.
2023 performance
Executed our plan and delivered on commitments
Drove operational performance and improved underlying operating margins;
exceeded earnings and cash flow expectations
Original Guidance
January 2023 2023 Actuals
Adjusted earnings per share $8.50 to $9.00 $9.24
Adjusted free cash flow conversion 90% to 100% 123%
Adjusted organic sales growth Flat to -3% -3%

-- 4 of 24 --

5
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Reducing risk
and uncertainty
• Combat Arms settlement continues to achieve
milestones amid strong support from claimants
• PWS settlement progressing
• PFAS manufacturing exit remains on track by
year-end 2025; 2023 PFAS production volumes
down ~20%
Spinning off
Health Care
• Spin remains on track for first-half 2024
Advancing our priorities:
Driving performance
through the 3M model
• Took actions to simplify the company; initiated restructuring
actions that drove strong benefits in 2023
• Improved adjusted operating margins to 20.3%, which includes
140 bps headwind from pre-tax restructuring charges
• Generated $6.3 billion in adjusted free cash flow, resulting in
conversion of 123%, up 37 ppts year-on-year
• Met or exceeded expectations throughout the year through
strong operational execution
• Driving future growth by streamlining our go-to-market
structures and investing in attractive markets such as
automotive electrification, climate technology, and industrial
automation
1 2
3

-- 5 of 24 --

6
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Q4 2023 performance
Driving margin and cash flow through operational execution
Adj. organic growth of -1.4%
Includes 60 bps headwind from disposable
respirator decline
• End-market trends played out
as anticipated
– Strength in automotive OEM
– Electronics stabilizing
– China and consumer retail
remain soft
– Disposable respirator decline
as expected
• Adjusted operating income
margin up 180 bps YoY,
includes 140 bps headwind
from restructuring & related
charges
• Continued strong operational
execution
• Corporate & Unallocated
benefit driven by costs moved
into business segments based
on final full-year performance;
no impact to total company
operating margins
• Adjusted free cash flow
conversion of 145%
• Remained focused on working
capital improvement;
inventory levels down $550M
year-on-year
• Continuing to invest in
growth, productivity, and
sustainability
• Adjusted EPS up 11% YoY
• Accelerated restructuring
actions; Q4 EPS impact of
$0.17 vs. guidance mid-point
of $0.14
• Adjusted tax rate of 14.9%, or
$0.06 EPS benefit vs.
guidance (FY 2023 guide of
~18%; Q3 YTD actual of
18.3%; implied Q4 of ~17%)
Adjusted Sales of $7.7B
vs. $7.6 to $7.7B guidance
Adjusted Op. Income
Margin of 20.9%
Adjusted EPS of $2.42
vs. $2.13 to $2.33 guidance
Adjusted Free Cash
Flow of $2.0B

-- 6 of 24 --

7
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Q4 2023 operating margin and EPS
Adjusted
operating
margin
Adjusted
earnings
per share Commentary
Q4 2022 19.1% $2.18
Total organic growth/
productivity/other +4.0% +$0.43
Disposable respirator -0.1% -$0.03 • Decline in COVID-related disposable respirator demand
Remaining organic growth/
productivity/other +4.1% +$0.46 • Benefits from productivity, sourcing actions, restructuring, spending discipline, and selling price
• Partially offset by lower sales volumes and growth, productivity, and sustainability investments
Restructuring & related charges -1.4% -$0.17 • Q4 2023 pre-tax charge of $109M
Raw material -0.1% -$0.01 • Carryover impact of raw material, logistics, and energy cost inflation
FX -0.7% -$0.07 • Net of hedge impact; Argentina devaluation
Other expense/income NA +$0.02 • Primarily lower net interest
Adjusted tax rate* NA +$0.05 • Q4 2023 adjusted tax rate of 14.9% versus 16.6% in Q4 2022
Shares outstanding NA -$0.01 • Average diluted shares up YoY
Q4 2023 20.9% $2.42
* The effect of income taxes on items that had specific tax rates are reflected within their respective impacts in the table above.

-- 7 of 24 --

8
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Adjusted free cash flow
$2.0B
Adjusted free cash flow
conversion
145%
Cash returned to
shareholders
$0.8B
Adjusted free cash flow • Q4: $2.0B, up 18% YoY
• FY: $6.3B, up 30% YoY
Adjusted free cash flow
conversion
• Q4: 145%, up 8 ppts YoY
• FY: 123%, up 37 ppts YoY
• FY: improvement driven by working capital, especially inventory
Adjusted capital
expenditures
• Q4: $308M, down 32% YoY
• FY: $1.4B, down 8% YoY
Net debt • Q4: $10.0B, down 17% YoY
Capital returned to
shareholders • Q4: dividends $0.8B
• FY: dividends $3.3B
Q4 2023 cash flow and balance sheet

-- 8 of 24 --

2023 Q4 Earnings | January 23, 2024. All rights reserved.
Business Group performance
Safety &
Industrial
Transportation &
Electronics Health Care Consumer

-- 9 of 24 --

10
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Business Group performance
FY 2023
Organic
growth
Adjusted
operating
margin
Q4 2023
Organic
growth
Adjusted
operating
margin Q4 Commentary
Safety &
Industrial
-5.1%
22.0%
-3.9%
19.7%
• Double digit organic growth in roofing granules, industrial adhesives and tapes flat, all other divisions declined
• Disposable respirator sales down ~$50M, and reduced segment organic growth by 1.6 ppts
• Adjusted operating margin -70 bps YoY; decline driven by lower sales volume partially offset by benefits from
restructuring, pricing, and strong spending discipline
Transportation
& Electronics*
-3.5%
21.0%
2.7%
20.9%
• Adjusted organic growth in advanced materials, automotive and aerospace, and commercial solutions; electronics flat and
transportation safety declined
• Consumer electronics stabilizing; closely monitoring demand trends
• Adjusted operating margins +380 bps YoY; benefits from restructuring, pricing, and strong spending discipline
Health Care
0.7%
19.6%
-1.0%
18.3%
• Organic growth in medical solutions; separation and purification, oral care and health information systems declined
• Operating margin -190 bps YoY; decline driven by lower volumes and costs to build out the team ahead of spin
• EBITDA margin of 25.5%
Consumer
-4.7%
18.0%
-2.2%
18.0%
• Organic growth in home improvement; home health and auto care, and stationery and office declined
• Operating margin +100 bps YoY; benefits from restructuring, portfolio optimization, spending discipline, and productivity,
partially offset by lower volume
• Continued softness in consumer discretionary spend
*"Transportation & Electronics” organic sales is provided on an adjusted basis while all other business segments are not provided on an adjusted basis

-- 10 of 24 --

2023 Q4 Earnings | January 23, 2024. All rights reserved.
2024 Outlook

-- 11 of 24 --

12
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Portfolio optimization
• Complete the spin of Health Care
• Execute on geographic prioritization
• Prioritizing high growth, high value product portfolios
• Drive growth through investments in the business
Reduce risk and uncertainty
• Finalize legal settlements
• Progress PFAS manufacturing exit
Sustainable margin and cash
• Simplify and streamline the organization
• Drive productivity throughout the supply chain
• Relentless focus on working capital
Positioning 3M for the future
2024 focus areas
Drive sustainable margin and cash flow
improvement through the 3M model
1
2
3
Portfolio optimization
Reduce risk and uncertainty

-- 12 of 24 --

13
2023 Q4 Earnings | January 23, 2024. All rights reserved.
2024 full-year guidance
Adjusted earnings
per share
Adjusted free cash
flow conversion
Adjusted organic
sales growth
Note: 2024 guidance approach includes the Health Care business as part of the company for the full year, but does not reflect the potential impact of funding
amounts due under the Public Water System and Combat Arms Earplug settlements, absent the receipt of cash payments in the Health Care business spin. See
additional details on earlier slide.
$9.35 to $9.75
95% to 105%
Flat to +2%
(Includes ~ 1 ppt headwind from
portfolio/geographic prioritization)

-- 13 of 24 --

14
2023 Q4 Earnings | January 23, 2024. All rights reserved.
2024 business group outlook
Below the line items
• Non-op pension expense headwind of $0.15 per share
• Expected adjusted tax rate range of 18.5% to 19.5%
Safety & Industrial
• Organic sales growth: flat to +LSD
• Industrial end-market demand mixed
• Industrial Production Index (IPI) up 2% (IHS)
Consumer
• Organic sales growth: -LSD
• Portfolio rationalization sales headwind of ~2 ppts
• Consumer discretionary spending muted
Transportation & Electronics
• Adjusted organic sales growth: flat to +LSD
• Auto builds slightly negative
• Consumer electronics demand up slightly
• Continued strong auto electrification growth
Health Care
• Organic sales growth: flat to +LSD
• Procedure volume growth +LSD
• Spin on track for 1H 2024

-- 14 of 24 --

15
2023 Q4 Earnings | January 23, 2024. All rights reserved.
• Macroeconomic trends similar to Q4
• Estimated combined sales headwind of ~$100M YoY from:
− Consumer product portfolio rationalization, disposable
respirator YoY comp and the exit of small countries
• Pre-tax restructuring charge of ($75M) to ($100M), or
($0.10) to ($0.15) per share
• Non-op pension headwind of $0.04 per share
• Adjusted tax rate range of 20% to 21%
Q1 2024 outlook
Performance drivers
Note: 2024 guidance approach includes the Health Care business as part of the company for the full year, but does not reflect the potential impact of funding
amounts due under the Public Water System and Combat Arms Earplug settlements, absent the receipt of cash payments in the Health Care business spin. See
additional details on earlier slide.
Adjusted earnings per share
Adjusted sales
$2.00 to $2.15
~$7.6 billion

-- 15 of 24 --

2023 Q4 Earnings | January 23, 2024. All rights reserved.
Q&A Mike Roman
Chairman of the Board and
Chief Executive Officer
Monish Patolawala
President and
Chief Financial Officer
Bruce Jermeland
Senior Vice President,
Investor Relations

-- 16 of 24 --

2023 Q4 Earnings | January 23, 2024. All rights reserved.
Appendix

-- 17 of 24 --

18
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Q4 2023 P&L
GAAP ($M)
Q4
2023
Q4
2022 Change
Sales $8,013 $8,079 (0.8)%
Gross profit $3,335 $3,494 (4.5)%
% to sales 41.6% 43.2% (1.6)%
SG&A $1,625 $2,146 (24.3)%
% to sales 20.3% 26.5% (6.2)%
R&D & related $467 $445 4.9%
% to sales 5.8% 5.5% 0.3%
Goodwill impairment expense $— $271 (100.0)%
% to sales —% 3.4% (3.4)%
Operating income (loss) $1,243 $632 96.7%
% to sales 15.5% 7.8% 7.7%
Net income (loss) $945 $541 74.8%
Earnings (loss) per share $1.70 $0.98 74.0%
Note: the term "N/M" used within the appendix references "not meaningful" for certain percent changes.

-- 18 of 24 --

19
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Q4 2023 adjusted sales recap
Americas EMEA APAC Worldwide
Organic growth 0.3 % (0.6)% (5.8)% (1.4)%
Acquisitions/divestitures 0.7 % (0.6)% (0.3)% 0.2 %
FX 0.5 % 5.1 % (0.9)% 0.9 %
Total growth 1.5 % 3.9 % (7.0)% (0.3)%

-- 19 of 24 --

20
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Q4 business segment information
*"Safety & Industrial", "Transportation & Electronics", "Corporate & Unallocated", "Total Operating Business Segment" and "Total" provided on an adjusted basis while
“Health Care” and “Consumer” are not provided on an adjusted basis
($M) Adjusted net sales* Q4 2023 adjusted sales growth* Adjusted operating income* Adjusted operating margin*
Business Groups
Q4
2023
Q4
2022
Organic
growth FX M&A
Total
sales
change
Q4
2023
Q4
2022 Percent
change
Q4
2023
Q4
2022
Safety & Industrial $2,661 $2,735 (3.9)% 1.2% —% (2.7)% $524 $556 (6.0)% 19.7% 20.4%
Transportation & Electronics $1,769 $1,692 2.7% 0.5% 1.3% 4.5% $370 $291 27.6% 20.9% 17.1%
Health Care $2,037 $2,044 (1.0)% 1.1% (0.4)% (0.3)% $372 $412 (9.7)% 18.3% 20.2%
Consumer $1,226 $1,244 (2.2)% 0.6% —% (1.6)% $221 $212 4.2% 18.0% 17.0%
Total Operating Business
Segment $7,693 $7,715 $1,487 $1,471
Corporate & Unallocated $— $1 $121 $5
Total $7,693 $7,716 (1.4)% 0.9% 0.2% (0.3)% $1,608 $1,476 9.1% 20.9% 19.1%

-- 20 of 24 --

21
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Additional GAAP sales detail
($M) GAAP Net Sales
Business Groups Q4 2023 Q4 2022
Abrasives 322 329
Automotive Aftermarket 304 309
Closure and Masking Systems 236 252
Electrical Markets 305 328
Industrial Adhesives and Tapes 531 526
Personal Safety 844 895
Roofing Granules 119 96
Total Safety & Industrial Business Group 2,661 2,735
Advanced Materials 287 296
Automotive and Aerospace 479 429
Commercial Solutions 406 390
Electronics 739 760
Transportation Safety 178 180
Total Transportation & Electronics Business Group 2,089 2,055
($M) GAAP Net Sales
Business Groups Q4 2023 Q4 2022
Health Information Systems 312 338
Medical Solutions 1,162 1,134
Oral Care 306 321
Separation and Purification Sciences 230 235
Other Health Care 27 16
Total Health Care Business Group 2,037 2,044
Construction and Home Improvement Markets 547 527
Home, Health and Auto Care 364 372
Stationery and Office 315 345
Total Consumer Business Group 1,226 1,244
Corporate and Unallocated — 1
Total 3M 8,013 8,079

-- 21 of 24 --

22
2023 Q4 Earnings | January 23, 2024. All rights reserved.
2023 to 2025 structural reorganization actions*
*Note: These are separate from 3M’s 2023 to 2025 PFAS exit actions.
(($M)
)
Q1 2023
Actual
Q2 2023
Actual
Q3 2023
Actual
Q4 2023
Actual
FY 2023
Actual
Restructuring & related net charges $52 $212 $68 $109 $441
Net benefits (YoY) - $89 $166 $162 $417
(($M) 2024
Estimated
Total
Program
Estimated
Restructuring & related net charges $250 to $350 $700 to $900
Net benefits (YoY) $150 to $250 $700 to $900

-- 22 of 24 --

23
2023 Q4 Earnings | January 23, 2024. All rights reserved.
Quarterly 2023 adjusted operating margin progression
+9.0%
Q1 2023
Adjusted
operating
margin
Q2 2023
Adjusted
operating
margin
Q3 2023
Adjusted
operating
margin
Q4 2023
Adjusted
operating
margin
FY 2023
Adjusted
Operating
margin
2022 22.0% 21.6% 21.6% 19.1% 21.1%
Total organic growth/
productivity/other -2.0% +0.9% +2.6% +4.0% +1.3%
Disposable respirator/
Russia exit -1.1% -0.5% -0.4% -0.1% -0.5%
Remaining organic growth/
productivity/ other -0.9% +1.4% +3.0% +4.1% +1.8%
Restructuring charges -0.5% -2.7% -0.8% -1.4% -1.3%
Raw materials -1.3% -0.3% -0.3% -0.1% -0.5%
FX -0.3% -0.2% 0.0% -0.7% -0.3%
Divestiture 0.0% 0.0% +0.1% ---- ----
Other expense/income NA NA NA NA NA
Adjusted tax rate NA NA NA NA NA
Shares outstanding NA NA NA NA NA
2023 17.9% 19.3% 23.2% 20.9% 20.3%
Note: The above refers to a non-GAAP measure (adjusted operating margin) for periods in addition to Q4 and full year 2023. For Q1-Q3,
refer to 3M’s 8-K's dated April 25, July 25, and October 24, 2023 for additional information.

-- 23 of 24 --



-- 24 of 24 --